United Capital Financial Advisers LLC Sells 141,083 Shares of Gilead Sciences, Inc. (GILD)

United Capital Financial Advisers LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 38.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 222,169 shares of the biopharmaceutical company’s stock after selling 141,083 shares during the period. United Capital Financial Advisers LLC’s holdings in Gilead Sciences were worth $16,614,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Parnassus Investments CA raised its holdings in Gilead Sciences by 2.5% during the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares in the last quarter. Hyman Charles D increased its stake in shares of Gilead Sciences by 35.9% in the fourth quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 1,100 shares during the period. James Investment Research Inc. increased its stake in shares of Gilead Sciences by 23.2% in the fourth quarter. James Investment Research Inc. now owns 40,524 shares of the biopharmaceutical company’s stock worth $2,903,000 after purchasing an additional 7,644 shares during the period. Accident Compensation Corp increased its stake in shares of Gilead Sciences by 3.2% in the fourth quarter. Accident Compensation Corp now owns 64,097 shares of the biopharmaceutical company’s stock worth $4,592,000 after purchasing an additional 2,000 shares during the period. Finally, Financial Advisors Network Inc. increased its stake in shares of Gilead Sciences by 1,964.0% in the fourth quarter. Financial Advisors Network Inc. now owns 127,330 shares of the biopharmaceutical company’s stock worth $9,122,000 after purchasing an additional 121,161 shares during the period. Institutional investors own 77.71% of the company’s stock.

Gilead Sciences opened at $71.29 on Thursday, according to MarketBeat. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. The company has a market cap of $93.40 billion, a price-to-earnings ratio of 8.33, a P/E/G ratio of -6.25 and a beta of 1.15. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.19). The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm’s revenue for the quarter was down 21.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.23 earnings per share. sell-side analysts predict that Gilead Sciences, Inc. will post 5.75 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, June 14th. Gilead Sciences’s payout ratio is 26.64%.

A number of equities analysts have recently commented on GILD shares. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a research note on Monday, February 19th. Leerink Swann reiterated a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Royal Bank of Canada reiterated a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a research note on Friday, February 23rd. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $88.00.

In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction that occurred on Friday, March 23rd. The stock was sold at an average price of $75.02, for a total transaction of $437,591.66. Following the sale, the director now directly owns 58,452 shares of the company’s stock, valued at $4,385,069.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $73.14, for a total value of $3,657,000.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at $224,376,112.68. The disclosure for this sale can be found here. Insiders have sold 190,834 shares of company stock worth $13,693,989 over the last ninety days. Company insiders own 1.16% of the company’s stock.

About Gilead Sciences

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit